Recent progress in poly(ethylenimine)-mediated gene delivery  by Godbey, W.T
JOURNAL OF VASCULAR SURGERY 
1294 Lifeline Research Meeting Abstracts June 2000 
adenoviral delivery stent has been formulated and 
has been shown to successfully deliver an adenovirus 
providing a reporter gene to the arterial wall of 
stented animals. 2 However, the adenoviral delivery 
system failed to adequately localize the vector in 
these studies, with widespread transduction i volv- 
ing multiple organ systems. Our laboratory has been 
involved in a plasmid DNA delivery stent, with a 
stent coating based on a polymeric emulsion solvent 
casting system. 3 This particular DNA system has 
been shown to have efficient expression of a reporter 
gene (green fluorescent protein [GFP]) in the arter- 
ial wall, with little evidence ofdistal spread per PCR. 
Recent therapeutic studies have also indicated 
expression of efficacious genetic onstructs in stent- 
ed pig coronary arteries. 
In conclusion, controlled release drug delivery 
stents offer a promising approach to both treating 
underlying arterial disease, as well as preventing in- 
stent restenosis. 
Thanks to Ginger Nicholson for preparing this presenta- 
tion. We also acknowledge grant support from he National 
Institutes of Health (HL41663), a grant from Selective 
Genetics, San Diego, Calif, and The William I. Rashldnd 
Endowment of The Children's Hospital of Philadelphia. 
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The major aim of gene therapy is to deliver genet- 
ic material into cells to alter their function, usually for 
the benefit of an entire organism. The genetic mater- 
ial can be either DNA or RNA, and the altered func- 
tion can be an increase or a decrease in the production 
of a protein. The protein is not restricted to being a 
natural product of the host cells, and the host cells are 
not required to be functioning as a part of the whole 
organism at the time of transfection. Fundamental 
problems involve deciding on and isolating the gene 
to deliver, getting it into the cells of interest, and 
achieving expression of the gene once it has entered 
the cells. The field of gene delivery focuses on the lat- 
ter two of these goals and has spawned aggressive 
research in many laboratories throughout the world. 
Fundamcntal pproaches to gene delivery can be 
classified as viral or nonviral. Of the nonviral methods, 
chemicals uch as cationic lipids and polycations have 
been examined in great detail. One of the most suc- 
cessful polycations used in gene delivcry research today 
is poly(ethylenimine) (PEI), which has been widely 
uscd for years in the paper industry. PEI is a highly 
polycationic synthetic polymer that is available in both 
linear and branched forms. It is known to condense 
DNA in solution, forming complexes that are readily 
endocytosed by many cell types. An overview of PEI 
chemistry, PEI /DNA characterization, and transfec- 
tion issues is given in reference 1. This abstract will 
serve to briefly introduce some of the most recent 
developments in PEI-mediated transfection that were 
not covered at the time of the review. 
One of the advantages of  using nonviral over 
viral gene carriers is that the nonviral vectors are not 
architecturally constrained to delivering plasmids at 
or below a given size. It has recently been shown 
that PEI and PLL are both able to deliver yeast arti- 
ficial chromosomes (YACs) of 2.3 Mb into mam- 
malian cells. 2 PEI's ability to compact its carried 
DNA appears to be an important factor in delivering 
large DNA constructs, as shown in the same experi- 
ments, where 67% of the successful PLL-mediated 
transfections suffered amage to the delivered chro- 
mosomes. Compare this to PEI-mediated elivery, 
where 0% of the successful transfections involved 
damage to the delivered YACs. 2 
The condensation of DNA by PEI is important 
for the delivery of smaller plasmids, as well. Whether 
administered in vitro or in vivo, there is potential for 
the PE I /DNA complexes to be exposed to degrada- 
rive nucleases. In the comparison of PEI with PLL, 
it has been shown that PEI offers vastly greater pro- 
tection to transported DNA against degradation by 
DNase i and DNase 2. 3 In these experiments, PEI 
helped preserve DNA, intact, in all conditions test- 
ed, even when the complexes were exposed to 25 to 
50 units of enzyme for 24 hours. Other nonviral 
transfection agents have been shown to offer protec- 
tion below the level given by PEI. For instance, the 
liposome forming agent dioctadecylamidogly- 
cylspermine (DOGS) (also known as Transfectam), 
while offering resistance to DNA against nuclease 
digestion, offered such protection at a level signifi- 
cantly lower than what was observed for linear PEI. 4 
Intuitively, the degradation of delivered DNA can 
lower the ultimate level of transgene xpression, so 
protection of the DNA during delivery is an impor- 
tant consideration toward transfection. 
PEI is not the ideal transfection agent, however. 
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Delivering undamaged DNA into cells is important, 
but of little consequence if the carrier also acts to kill 
the host cells. While in vivo data indicate that there 
is no more immune response than an acute neu- 
trophilic reaction to aerosol delivery of PEI into rab- 
bit lungs, even when the PE I /DNA complexes are 
delivered repeatedly over 21 days, four other data 
show a great deal of toxicity on the cellular level. 
Fischer et al S demonstrated PEI's cytotoxic effects 
with transmission electron microscopy, and Putnam 
and Langer 6 resorted to developing a novel vector 
because of the overwhelming cytotoxicity of PEI- 
mediated gene delivery (which yielded a reported 2% 
cell survival rate). While we have not seen a level of 
cell death as dramatic as 98%, our own work has 
demonstrated a significant level of PEI-induced cell 
death during cellular exposure to both free and 
DNA-complexed PEI. 7 
PEI has been conjugated with charge-neutralizing 
entities to yield zeta potentials closer to neutrality for 
transfection complexes, to partially overcome its toxic 
effects. Conjugation of transferrin-PEI/DNA com- 
plexes with polyethylene glycol not only yields com- 
plexes with lower zeta potentials, but is also responsi- 
ble for decreased aggregation of complexes with 
themselves, decreased interactions with plasma pro- 
teins, and decreased toxicity.8 The reduced complex 
aggregation and blood protein interactions allow the 
complexes to circulate for longer periods of time in 
vivo and improve the targeting aspects of the transfer- 
rin-containing complexes perhaps because of 
decreased nonspecific interactions involving the high- 
ly cationic PEI. All of this has been gained with a min- 
imal change in transfection efficiency (in in vitro 
experiments). 8 
Other recent examples of research involving con- 
jugated PEI include the attachment of sugar moi- 
eties to PEI for targeting purposes. Mannosylated 
PEI has been used to target conjugate/DNA com- 
plexes to antigen-presenting cells with limited suc- 
cess. 9 Although targeting was achieved through 
interaction of the complexes with mannose recep- 
tors, the number of cells expressing the delivered 
reporter gene was very low. Adenoviral particles 
were then attached to the mannose-PE I /DNA 
complexes to improve transfection efficiency, but it 
was found that the complexes no longer entered the 
tested cells through pathways using mannose recep- 
tors. 9 (Although the mannose conjugation did not 
produce good transfection results, the value of con- 
jugation of PEI with adenoviral particles was 
demonstrated.) Another sugar that has been conju- 
gated with PEI for transfection is galactose, in this 
case for the purpose of hepatocyte targeting. 1° 
While the results of such conjugation were success- 
ful, it has been shown that the transfection efficien- 
cy of galactose-PEI/DNA complexes can be 
improved, without a loss in cell specificity, by manip- 
ulating the length of the conjugated galactose 
chains) 1 These experiments showed that transfec- 
don efficiency was increased when the conjugated 
complexes had a reduced overall size. 
Other PEI research as been published along 
lines that are more clinically oriented. For instance, 
while one of the benefits of polycationic gene deliv- 
ery methods is that the delivery vehicles are relative- 
ly easy to store, the storage issue was taken a step fur- 
ther when it was shown that transferrin-PEI/DNA 
(along with transferrin-polylysine/DNA and a ver- 
sion of adenovirus) could be successfully freeze dried 
and rehydrated for use weeks later. 12 This has the 
potential to make gene delivery accessible in a wider 
array of clinical settings. Another development in
PEI research, which used an engineering approach to 
aid gene delivery, used micropumps to slowly (20 
mL/min) deliver PEI /DNA complexes to a specific 
solid mass tumor type in vivo. 13 It was found that 
there are instances where slow delivery of PEI /DNA 
complexes yields transfection results that are 
improved over rapid syringe injection or systemic 
delivery of complexes. 
In the limited space provided we have offered 
some of the most recent developments in PEI-medi- 
ated gene transfer. The field continues to advance 
and expand to address issues pertinent to any nonvi- 
ral method of gene delivery. Because of toxicity and 
targeting issues, research into conjugates of PEI with 
other component molecules i a rapidly growing area. 
This abstract also presented peripheral issues that 
might eventually prove to be clinically relevant, issues 
such as freeze drying of gene delivery complexes for 
long-term storage and ease of transport and 
improved transfection efficiency in vivo through the 
slow delivery rates of a micropump. There is much 
work that has yet to bc performed before PEI, or any 
other nonviral gene delivery vehicle, can be a viable 
option for the treatment of certain human condi- 
tions. However, every passing month seems to yield 
important advances in gene delivery technology that 
are helping to reach that end. 
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For all therapeutic options local drug delivery 
should in theory be the preferred way of ensuring 
adequate drug is delivered to the pathological site 
without the risks of side effects. It  would appear illog- 
ical to administer a drug systemically to treat perhaps 
only 20 to 30 mm of the coronary artery. Large sys- 
temic doses may be required to achieve adequate 
doses of drug locally, with the risk of systemic side 
effects. Sometimes agents hown to be effective in sys- 
temic doses in an animal model cannot be given to 
man in the same dose or are shown in clinical trials as 
a result o be ineffective. A good example was the lack 
of efficacy of ACE inhibitors in human trials ofangio- 
plasty restenosis despite their proven value in the rat 
and rabbit models: the dose effective in the model was 
10 times that which could be tolerated by man. It 
would have been better to have calculated the dose 
required locally and to have delivered that locally. 
Local drug delivery can be achieved using appropri- 
ately designed balloons. A number of  these and a 
number of agents have been extensively investigated 
in vitro and in animal studies. There are three major 
problems with local drug delivery. First, it is not local; 
many studies have shown that regional distribution f 
an agent occurs. Thus drug delivered to the coronary 
arteries could affect myocardial cell function. Second, 
efficiency of delivery is poor, with only 2% to 5% of 
drug being delivered to the site. Part of this is loss of 
drug from the device and part is lack of retention. 
While it is always difficult to determine how much (or 
how little) drug is needed locally, such studies do at 
least suggest hat the majority of drug (> 95%) is not 
locally retained and is therefore in the systemic ircu- 
lation. The final major problem is the lack of retention 
itself. There appears no reason, except for the passive 
adsorption of  antibodies to smooth muscle cells for 
example, for the drug to stay where it is delivered. 
In our laboratory we have, over a number of  
years, explored the possibility of improving reten- 
tion and therefore fficacy of drugs delivered locally 
by the development of conjugates. Our initial work 
developed the concept of targeting through the use 
of  localizing agents. Thus a conjugate would in 
effect be the combination of a localizing agent, usu- 
ally an antibody directed against a particular compo- 
nent of  the vessel wall, that was expressed by the 
pathological process, combined through a chemical 
process to the effector agent, a lower than systemic 
dose of the active drug. Initial studies assessed an 
antibody against damaged vessel wall (P14Gl l )  
conjugated using SPDP to a glycoprotein I Ib /U Ia  
receptor blocker. Delivering this conjugate with an 
LDD balloon not only reduced restenosis in an in 
vivo model of angioplasty at a dose seven times less 
than would have been required systemically, but 
measures of systemic effects were not seen. 
Since this early work we have been studying the 
development of  bispecific antibodies. Such mole- 
cules are formed by choosing the two antibodies: 
one localizing and one ffector. These antibodies are 
deconstructed enzymatically, and two monovalent 
Fabs of the separate antibodies are recombined by 
reestablishing the interheavy chain disulphide 
bonds. Thus we have prepared a novel bispecific 
molecule with one arm being the monovalent Fab of  
a glycoprotein I Ib / I I I a  receptor blocker and the 
other the monovalent Fab of  an antibody (AP1) 
